Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Equine Vet Sci ; 86: 102898, 2020 03.
Article in English | MEDLINE | ID: mdl-32067665

ABSTRACT

Lameness remains a common cause of retirement in the equine athlete and among hobby enthusiasts. The distal limb is one of the most frequently imaged areas, and recent advances in diagnostic imaging capabilities help practicing veterinarians differentiate normal variants from informative pathology. Although acute, non-weight-bearing lameness is commonly associated with etiologies, such as fractures, abscesses, and laminitis, other uncommon differentials such as cystic lesions and neoplasia might also be considered. This report describes the characterization of a large, cystic lesion in the third phalanx (P3), which resulted in an acute, pathologic fracture. The lesion was fully characterized with the use of postmortem magnetic resonance imaging, gross pathology, and histopathology.


Subject(s)
Fractures, Spontaneous , Horse Diseases , Animals , Fractures, Spontaneous/veterinary , Horses , Magnetic Resonance Imaging , Multimodal Imaging
2.
J Orthop Res ; 37(6): 1310-1317, 2019 06.
Article in English | MEDLINE | ID: mdl-30578639

ABSTRACT

Optimizing the environment of complex bone healing and improving treatment of catastrophic bone fractures and segmental bone defects remains an unmet clinical need both human and equine veterinary medical orthopaedics. The objective of this study was to determine whether scAAV-equine-BMP-2 transduced cells would induce osteogenesis in equine bone marrow derived mesenchymal stem cells (BMDMSCs) in vitro, and if these cells could be cryopreserved in an effort to osteogenically prime them as an "off-the-shelf" gene therapeutic approach for fracture repair. Our study found that transgene expression is altered by cell expansion, as would be expected by a transduction resulting in episomal transgene expression, and that osteoinductive levels could still be achieved 5 days after recovery, and protein expression would continue up to 14 days after transduction. This is the first evidence that cryopreservation of genetically modified BMDMSCs would not alter the osteoinductive potential or clinical use of allogeneic donor cells in cases of equine fracture repair. © 2018 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 37:1310-1317, 2019.


Subject(s)
Bone Morphogenetic Protein 2/genetics , Cryopreservation , Fracture Healing , Genetic Therapy/methods , Animals , Dependovirus/genetics , Horses , Transduction, Genetic
3.
J Orthop Res ; 36(6): 1559-1572, 2018 06.
Article in English | MEDLINE | ID: mdl-29280510

ABSTRACT

Conventional clinical management of complex bone healing scenarios continues to result in 5-10% of fractures forming non-unions. Additionally, the aging population and prevalence of osteoporosis-related fractures necessitate the further exploration of novel ways to augment osteogenesis in this special population. This review focuses on the current clinical modalities available, and the ongoing clinical and pre-clinical research to promote osteogenesis in segmental bone defects, delayed unions, and osteoporosis. In summary, animal models of fracture repair are often small animals as historically significant large animal models, like the dog, continue to gain favor as companion animals. Small rodents have well-documented limitations in comparing to fracture repair in humans, and few similarities exist. Study design, number of studies, and availability of funding continue to limit large animal studies. Osteoinduction with rhBMP-2 results in robust bone formation, although long-term quality is scrutinized due to poor bone mineral quality. PTH 1-34 is the only FDA approved osteo-anabolic treatment to prevent osteoporotic fractures. Limited to 2 years of clinical use, PTH 1-34 has further been plagued by dose-related ambiguities and inconsistent results when applied to pathologic fractures in systematic human clinical studies. There is limited animal data of PTH 1-34 applied locally to bone defects. Gene therapy continues to gain popularity among researchers to augment bone healing. Non-integrating viral vectors and targeted apoptosis of genetically modified therapeutic cells is an ongoing area of research. Finally, progenitor cell therapies and the content variation of patient-side treatments (e.g., PRP and BMAC) are being studied. © 2017 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 36:1559-1572, 2018.


Subject(s)
Fracture Healing/physiology , Fractures, Bone/physiopathology , Osteogenesis/physiology , Osteoporotic Fractures/physiopathology , Animals , Bone Morphogenetic Protein 2/therapeutic use , Disease Models, Animal , Fractures, Bone/therapy , Genetic Therapy , Humans , Osteoporotic Fractures/therapy , Parathyroid Hormone/therapeutic use , Stem Cell Transplantation
SELECTION OF CITATIONS
SEARCH DETAIL
...